We narrowed to 184 results for: GCaMP6f

#213859-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiVIPe4_GCaMP6f (#213859). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the VIP interneuron-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213818-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiSSTe10_GCaMP6f (#213818). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the SST interneuron-targeting enhancer E10. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#179529-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-4mtGCaMP6f-DIO (#179529). In addition to the viral particles, you will also receive purified pAAV-EF1a-4mtGCaMP6f-DIO plasmid DNA. EF1a-driven, Cre-dependent expression of mitochondria-targeted GCaMP8f. These AAV preparations are suitable purity for injection into animals.

Maarten Kole

Kole et al Nat Commun. 2022 Dec 9;13(1):7598. doi:

Feb. 6, 2026

Academic Institutions and Nonprofits only